Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting
Cerus (CERS) announced a selection of abstracts to be presented at the 2024 AABB Annual Meeting in Houston, Texas from October 19-22. The presentations highlight real-world utilization of INTERCEPT-treated blood products, including INTERCEPT Fibrinogen Complex, and recent findings from the Phase 3 ReCePI Clinical Trial.
Key presentations include:
- Outcomes of the ReCePI Phase III Clinical Trial evaluating pathogen-reduced red cells in cardiac surgery
- Efficiency of INTERCEPT Fibrinogen Complex vs traditional cryoprecipitate
- Phase IV TOPCLOT trial comparing pathogen-reduced cryoprecipitate to cryoprecipitated AHF in cardiac surgery
- HLA alloimmunization and treatment-emergent antibodies in the ReCePI study
Poster presentations will cover topics such as pathogen reduction efficacy, next-generation illuminator development, and implementation of pathogen-reduced blood products. Cerus will also host an industry workshop on current experiences and future developments with the INTERCEPT Blood System.
Cerus (CERS) ha annunciato una selezione di abstract che saranno presentati alla Riunione Annuale AABB 2024 a Houston, Texas, dal 19 al 22 ottobre. Le presentazioni evidenziano l'utilizzo reale dei prodotti ematici trattati con INTERCEPT, compreso il Complesso di Fibrinogeno INTERCEPT, e le recenti scoperte provenienti dal Trial Clinico di Fase 3 ReCePI.
Le presentazioni chiave includono:
- Esiti del Trial Clinico di Fase III ReCePI che valuta le cellule rosse ridotte per patogeni in chirurgia cardiaca
- Efficienza del Complesso di Fibrinogeno INTERCEPT rispetto al crioprecipitato tradizionale
- Trial di Fase IV TOPCLOT che confronta il crioprecipitato ridotto per patogeni con il crioprecipitato AHF in chirurgia cardiaca
- Alloimmunizzazione HLA e anticorpi emergenti dal trattamento nello studio ReCePI
Le presentazioni poster tratteranno argomenti come l'efficacia della riduzione dei patogeni, lo sviluppo di illuminatori di nuova generazione e l'implementazione di prodotti ematici ridotti per patogeni. Cerus ospiterà anche un workshop del settore sulle esperienze attuali e gli sviluppi futuri con il Sistema Ematico INTERCEPT.
Cerus (CERS) anunció una selección de resúmenes que se presentarán en la Reunión Anual de AABB 2024 en Houston, Texas, del 19 al 22 de octubre. Las presentaciones destacan la utilización en el mundo real de los productos sanguíneos tratados con INTERCEPT, incluido el Complejo de Fibrinógeno INTERCEPT, y los hallazgos recientes del Ensayo Clínico de Fase 3 ReCePI.
Las presentaciones clave incluyen:
- Resultados del Ensayo Clínico de Fase III ReCePI que evalúa células rojas reducidas por patógenos en cirugía cardíaca
- Eficiencia del Complejo de Fibrinógeno INTERCEPT vs. crioprecipitado tradicional
- Ensayo de Fase IV TOPCLOT comparando crioprecipitado reducido por patógenos con crioprecipitado AHF en cirugía cardíaca
- Alóinmunización HLA y anticuerpos emergentes por el tratamiento en el estudio ReCePI
Las presentaciones de cartel abordarán temas como la eficacia de la reducción de patógenos, el desarrollo de iluminadores de nueva generación y la implementación de productos sanguíneos reducidos por patógenos. Cerus también organizará un taller de la industria sobre experiencias actuales y desarrollos futuros con el Sistema de Sangre INTERCEPT.
Cerus (CERS)는 2024 AABB 연례 회의에서 발표할 초록 선택사항을 발표했습니다. 회의는 텍사스주 휴스턴에서 10월 19일부터 22일까지 열립니다. 발표들은 INTERCEPT 처리된 혈액 제품의 실제 활용, INTERCEPT 피브리노겐 복합체를 포함한 내용과 3상 ReCePI 임상 시험의 최근 발견을 강조합니다.
주요 발표 내용은 다음과 같습니다:
- 심장 수술에서 병원체 감소 적혈구를 평가하는 ReCePI 3상 임상 시험의 결과
- INTERCEPT 피브리노겐 복합체와 전통적인 크리오석출물의 효율성
- 심장 수술에서 병원체 감소 크리오석출물과 크리오석출물 AHF를 비교하는 4상 TOPCLOT 시험
- ReCePI 연구에서의 HLA 알로면역화 및 치료 시 발생하는 항체
포스터 발표는 병원체 감소 효능, 차세대 조명기 개발, 병원체 감소 혈액 제품의 구현 등의 주제를 다룰 것입니다. Cerus는 또한 INTERCEPT 혈액 시스템과 관련된 현재의 경험 및 향후 개발에 대한 산업 워크숍을 개최할 것입니다.
Cerus (CERS) a annoncé une sélection d'abstracts qui seront présentés lors de la Réunion Annuelle AABB 2024 à Houston, Texas, du 19 au 22 octobre. Les présentations mettent en avant l'utilisation réelle des produits sanguins traités avec INTERCEPT, y compris le Complexe de Fibrinogène INTERCEPT, et des résultats récents de l'Essai Clinique de Phase 3 ReCePI.
Les présentations clés comprennent :
- Résultats de l'Essai Clinique de Phase III ReCePI évaluant les globules rouges réduits pour les agents pathogènes en chirurgie cardiaque
- Efficacité du Complexe de Fibrinogène INTERCEPT par rapport au cryoprécipité traditionnel
- Essai de Phase IV TOPCLOT comparant le cryoprécipité réduit pour les agents pathogènes au cryoprécipité AHF en chirurgie cardiaque
- Alloimmunisation HLA et anticorps émergents du traitement dans l'étude ReCePI
Les présentations par affiches couvriront des sujets tels que l'efficacité de la réduction des agents pathogènes, le développement d'illuminants de nouvelle génération et la mise en œuvre de produits sanguins réduits pour les agents pathogènes. Cerus organisera également un atelier de l'industrie sur les expériences actuelles et les développements futurs avec le Système Sanguin INTERCEPT.
Cerus (CERS) hat eine Auswahl von Abstracts angekündigt, die auf dem AABB Jahreskongress 2024 in Houston, Texas, vom 19. bis 22. Oktober vorgestellt werden. Die Präsentationen heben die praktische Nutzung von INTERCEPT-behandelten Blutprodukten hervor, einschließlich des INTERCEPT Fibrinogenkomplexes, sowie aktuelle Erkenntnisse aus der Phase 3 ReCePI-Studie.
Wichtige Präsentationen umfassen:
- Ergebnisse der ReCePI Phase III-Studie zur Bewertung von pathogenreduzierten Erythrozyten bei Herzchirurgie
- Effizienz des INTERCEPT Fibrinogenkomplexes im Vergleich zu traditionellem Kryopräzipitat
- Phase IV TOPCLOT-Studie zum Vergleich von pathogenreduziertem Kryopräzipitat mit kryopräzipitierten AHF in der Herzchirurgie
- HLA-Alloimmunisierung und behandlungsbedingte Antikörper in der ReCePI-Studie
Posterpräsentationen werden Themen wie die Wirksamkeit der Pathogenreduktion, die Entwicklung von illuminierenden Geräten der nächsten Generation und die Umsetzung von pathogenreduzierten Blutprodukten abdecken. Cerus wird auch einen Branchenworkshop zu aktuellen Erfahrungen und zukünftigen Entwicklungen mit dem INTERCEPT-Blut-System veranstalten.
- Presentation of Phase 3 ReCePI Clinical Trial results for INTERCEPT-treated red blood cells
- Multiple studies showcasing efficiency and benefits of INTERCEPT Fibrinogen Complex
- Ongoing development of next-generation illuminator for pathogen inactivation in platelet concentrates
- Industry workshop highlighting current experiences and future developments with INTERCEPT Blood System
- None.
Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical Trial
The following is a select list of Cerus-related presentations and abstracts. All presentation times are listed in Central Daylight Time (CDT).
Oral Presentations
- Sunday, October 20, 2024 – 9:30 a.m.– Acute Kidney Injury to Evaluate Amustaline/Glutathione Pathogen Reduced Red Cells in Cardiac Surgery: Outcomes of the ReCePI Phase III Clinical Trial (Speaker: E. Snyder)
- Monday, October 21 – 9:45 a.m. – Utilizing Sankey Diagrams to Quantify Laboratory Efficiency of INTERCEPT Fibrinogen Complex vs Traditional Cryoprecipitate (Speaker: D. Chen)
-
Monday, October 21, 2024 – 2:00 p.m. – Phase IV Trial of Pathogen-reduced Cryoprecipitate vs. Cryoprecipitated AHF to Lower Operative Transfusions (TOPCLOT) in Cardiac Surgery (Speaker: M.
Cushing ) - Monday, October 21, 2024 – 2:00 p.m. – HLA Alloimmunization in ReCePI, a Phase III Study of Amustaline/Glutathione Pathogen Reduced RBCs (Speaker: P. Norris)
- Monday, October 21, 2024 – 2:00 p.m. – Treatment-Emergent Antibodies to Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in the ReCePI Phase III Clinical Trial (Speaker: R. Benjamin)
Poster Presentations
Held Sunday, October 20 and Monday, October 21, 2024
- Evaluation of Pathogen Reduction Efficacy in Platelet Concentrates Until End of Shelf-Life with Two Different Automated Bacterial Detection Systems
- Development of a Next Generation Illuminator for Photochemical Inactivation of a Broad Spectrum of Pathogens in Platelet Concentrates
- Accelerating Treatment Delivery and Reducing Waste with Implementation of Pathogen Reduced Cryoprecipitated Fibrinogen Complex
- Wastage and Cost Analysis for INTERCEPT Fibrinogen Complex
- An Analysis of Anesthesiologist and Transfusion Service Staff Preferences Between Pathogen Reduced Cryoprecipitated Fibrinogen Complex and Conventional Cryoprecipitated AHF
- Analysis of Wastage, Savings, and Maternal and Pediatric Outcomes for Pooled Pathogen Reduced Cryoprecipitate versus Conventional Cryoprecipitate
- Pathogen Reduced Cryoprecipitate Implementation and Assessment of Its Impact in a Large Academic Medical Center
- Implementation of INTERCEPT Fibrinogen Complex (IFC) for Postpartum Hemorrhage
- Evaluation of INTERCEPT RBC Pathogen Reduction in Combination with Irradiation
Industry Workshop
- Monday, October 21, 2024 – 7:00 a.m.– Industry Workshop Presented by Cerus: Pathogen Reduced Blood Components – Current Experiences and Future Developments with the INTERCEPT® Blood System (Speakers: J. Squires, C. Ingold, E. Snyder)
The full program of Cerus-related abstracts can be found at the following link: https://intercept-usa.com/wp-content/uploads/sites/8/2024/09/2024_AABB_AbstractBook_v6final_27Sept2024.pdf
Cerus representatives will be in the exhibition area at booth #431.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241018604249/en/
Jessica Hanover
Cerus Corporation
925-288-6137
Source: Cerus Corporation
FAQ
What are the key topics being presented by Cerus (CERS) at the 2024 AABB Annual Meeting?
When and where is the 2024 AABB Annual Meeting where Cerus (CERS) will present its research?
What is the focus of the industry workshop presented by Cerus (CERS) at the 2024 AABB Annual Meeting?
What types of blood products are being discussed in Cerus 's (CERS) presentations at the 2024 AABB Annual Meeting?
